RxDoctor Payments Data

Joseph Lucas, MD

Psychiatry · Birmingham, ALNPI 1538118500

Payments from drug & device makers

$3,807in general payments, 2019–2025

Across 195 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$575
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$547
  • Axsome Therapeutics, Inc.$546
  • Teva Pharmaceuticals USA, Inc.$418
  • Otsuka America Pharmaceutical, Inc.$345
  • Lundbeck LLC$278
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,807100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,807 in reported general payments places this provider in the 80th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$145,381
Medicare patients
367
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl39$63,287
RexultiBrexpiprazole32$44,726
Invega SustennaPaliperidone Palmitate16$40,342
Abilify MaintenaAripiprazole12$35,138
TrintellixVortioxetine Hydrobromide32$29,850
Aripiprazole298$29,331
Lurasidone Hcl62$26,784
CaplytaLumateperone Tosylate12$18,748
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl45$12,083
Quetiapine Fumarate654$11,296
Ziprasidone Hcl115$10,246
Lamotrigine ErLamotrigine23$10,044
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine264$8,911
Duloxetine Hcl313$8,041
Clonazepam1,033$7,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$345$79,86444 claims
AbbVieVraylar, Viibryd$575$66,86350 claims
Johnson & JohnsonInvega Sustenna$166$40,34216 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$42$35,29846 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$547$18,74812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →